Back to top
more

Charles River Laboratories International, Inc. (CRL)

(Real Time Quote from BATS)

$320.02 USD

320.02
221,552

-12.86 (-3.86%)

Updated May 11, 2021 10:53 AM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 18% (208 out of 254)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

ETF Strategies to Hedge Against Inflation

Here are some ways to protect your portfolio from rising inflation.

Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates

Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.

Company News for Feb 18, 2021

Companies in the news are: CRL, VIR, LODE, CLPS

Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates

Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).

Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings

LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.

Why Charles River (CRL) Could Beat Earnings Estimates Again

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

Charles River (CRL) Soars to 52-Week High, Time to Cash Out?

Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

3 Reasons Growth Investors Will Love Charles River (CRL)

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.

Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

Charles River Laboratories (CRL) Q2 Earnings and Revenues Beat Estimates

Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Healthcare Stock Q2 Earnings Roster for Aug 5: HUM, CRL & More

The healthcare sector is expected to have benefited from solid demand for medical products and services in Q2, given the rising incidence of coronavirus cases as well as an ageing U.S. populace.

Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?

Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West

Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West

Moving Average Crossover Alert: Charles River Laboratories International

Charles River Laboratories International, Inc. (CRL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

4 GARP Stocks to Scoop Up for Maximum Returns

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Charles River Laboratories' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Charles River Laboratories.